Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,813 | 8 | 92.6% |
| Food and Beverage | $144.58 | 2 | 7.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,813 | 8 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $125.00 | 1 | $0 (2022) |
| ITI, Inc. | $19.58 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,813 | 8 | ABBVIE INC. ($1,813) |
| 2023 | $19.58 | 1 | ITI, Inc. ($19.58) |
| 2022 | $125.00 | 1 | IDORSIA PHARMACEUTICALS US INC ($125.00) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/22/2024 | ABBVIE INC. | — | — | In-kind items and services | $783.02 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $348.25 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $69.99 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $59.99 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/21/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/20/2024 | ABBVIE INC. | — | — | In-kind items and services | $348.25 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 09/20/2024 | ABBVIE INC. | — | — | In-kind items and services | $153.77 | Research |
| Study: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ||||||
| 03/31/2023 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: PSYCHIATRY | ||||||
| 11/17/2022 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INSOMNIA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | ABBVIE INC. | $1,813 | 8 |
About Crystal Mcglothlin, FNP
Crystal Mcglothlin, FNP is a Nurse Practitioner healthcare provider based in Cedar Bluff, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2009. The National Provider Identifier (NPI) number assigned to this provider is 1689801425.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Crystal Mcglothlin, FNP has received a total of $1,958 in payments from pharmaceutical and medical device companies, with $1,813 received in 2024. These payments were reported across 10 transactions from 3 companies. The most common payment nature is "" ($1,813).
Practice Information
- Specialty Nurse Practitioner
- Location Cedar Bluff, VA
- Active Since 06/19/2009
- Last Updated 06/19/2009
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1689801425
Products in Payments
- QUVIVIQ (Drug) $125.00
- CAPLYTA (Drug) $19.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Cedar Bluff
Mellissa Potter, Aprn, Fnp-Bc, APRN, FNP-BC
Nurse Practitioner — Payments: $23.36
Mrs. Emalene Cook, Rn Np, RN NP
Nurse Practitioner
Mr. Heath Clevinger, Fnp, FNP
Nurse Practitioner
Bell Charles, Fnp-C, FNP-C
Nurse Practitioner